Posted by Michael Wonder on 07 Feb 2023
Aldeyra Therapeutics announces FDA acceptance of new drug application for reproxalap for the treatment of dry eye disease
7 February 2023 - PDUFA date is 23 November 2023.
Aldeyra Therapeutics today announced that the US FDA has accepted the new drug application for topical ocular reproxalap, a first in class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease.
